Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (RTKi) compounds to the eye
US8912236B2 · kind B2 · utility
0Cited by
24References
7Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 3, 2010 |
| Grant date | Dec 16, 2014 |
| Priority date | — |
| Expiry date | May 29, 2031 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P27/02
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to development of efficacious pharmaceutical implant compositions comprising an active agent in a therapeutically effective amount and a polyethylene glycol having a molecular weight of at least 2000.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.